Optimising infliximab induction dosing for patients with ulcerative colitis.

ABSTRACT:

Aims

The therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even 2 decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintenance therapy, but induction therapy has still not been explored. Patients may be primary nonresponders or underexposed with the standard dosing regimen. We aimed to: (i) develop a population pharmacokinetic-pharmacodynamic model; (ii) identify the best exposure metric that predicts mucosal healing; and (iii) build an exposure-response (ER) model to demonstrate model-based dose finding during induction therapy with infliximab.

Methods

Data were retrospectively collected from a clinical database. A total of 583 samples, from 204 patients, was used to develop a population pha

SUBMITTER: Dreesen E 

PROVIDER: S-EPMC6422726 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature